Our results suggest that ICB compensates for an ineffective anti-tumor immunity associated with elevated PD-L1 expression in the tumors of VSG mice to restore markers of cytotoxic T cell response, which leads to reduced tumor burden. This evidence concerns the gene CD274 and neoplasm.